Trevi Therapeutics, Inc.

TRVISEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1563880

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$23.7M	$19.8M	$23.0M	$22.3M	$19.3M
Operating Expenses	$33.9M	$29.9M	$32.5M	$32.5M	$26.6M
Operating Income (Loss)	-$33.9M	-$29.9M	-$32.5M	-$32.5M	-$26.6M
Interest Expense	—	$1.2M	$1.2M	$456.0K	$456.0K
Nonoperating Income (Expense)	$4.8M	$719.0K	-$1.5M	-$287.0K	$577.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$29.1M	-$29.2M	-$34.0M	-$32.8M	-$26.1M
Income Tax Expense (Benefit)	-$32.0K	-$36.0K	-$21.0K	-$18.0K	-$18.0K
Net Income (Loss) Attributable to Parent	-$29.1M	-$29.2M	-$33.9M	-$32.8M	-$26.1M
Earnings Per Share, Basic	-$0.29	-$0.45	-$1.49	—	—
Earnings Per Share, Diluted	-$0.29	-$0.45	-$1.49	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$89.4M	$123.0M	$38.5M	$47.1M	$60.0M
Assets, Current	$87.5M	$122.6M	$38.0M	$46.3M	$59.6M
Cash and Cash Equivalents, at Carrying Value	$32.4M	$12.6M	$36.8M	$45.0M	$57.3M
Liabilities	$6.9M	$15.6M	$21.4M	$19.8M	—
Liabilities, Current	$5.8M	$13.4M	$12.7M	$5.6M	$5.2M
Accounts Payable, Current	$1.8M	$2.9M	$2.8M	$2.0M	$1.6M
Stockholders' Equity Attributable to Parent	$107.5M	$17.1M	$27.3M	$54.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$31.7M	-$28.2M	-$28.9M	-$29.0M	-$23.1M
Net Cash Provided by (Used in) Investing Activities	$59.4M	-$107.4M	-$107.4M	-$32.0K	-$9.0K
Net Cash Provided by (Used in) Financing Activities	-$7.9M	$111.3M	$20.8M	$16.7M	$73.2M
Payments to Acquire Property, Plant, and Equipment	$137.0K	$159.0K	$159.0K	$32.0K	$9.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)